Aegera Therapeutics Inc. - Intellectual Property

•	Aegera has an extensive patent portfolio which includes over 100 issued patents and pending patent applications worldwide.

•	Aegera has a dominant patent position around the Inhibitor of Apoptosis Proteins (IAPs), a family of proteins which play a fundamental role in apoptosis control.

	•	For this alone, Aegera has twenty-nine (29) issued US patents covering the majority of known IAPs including XIAP, cIAP1, cIAP2, TIAP, and NAIP.

	•	Aegera’s patent portfolio provides a unique strategic advantage in both antisense and small molecule discovery, which target diseases arising from the dysregulation of apoptosis, such as cancer.

•	Aegera’s portfolio also includes pending patent applications covering our small molecule antagonists of the IAP protein family and;

•	A number of pending patent applications cover our small molecules for the treatment of neuropathies, and line extensions thereof,